Overview

* Nuvectis Pharma ( NVCT ) Q3 net loss widens to $7.5 mln due to milestone expenses

* Cash position increased to $35.4 mln, supporting operations into Q3-2027

* NXP900 Phase 1b program initiated, focusing on advanced cancers

Outlook

* Nuvectis expects cash reserves to support operations into 3Q-2027

* Company plans to initiate NXP900 combination therapy component by year-end

* Nuvectis aims to achieve key milestones for NXP900 Phase 1b program

Result Drivers

* MILESTONE EXPENSES - Increase in net loss due to a one-time $2.0 mln milestone achievement expense for NXP900

* CASH POSITION - Cash and cash equivalents were $35.4 million as of September 30, 2025, compared to $18.5 million as of December 31, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.44

Q3 -$7.79

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Nuvectis Pharma Inc ( NVCT ) is $18.50, about 65.6% above its November 3 closing price of $6.36

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)